Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4+ and CD8+ T cells

Yusuke Tomita; Yasuharu Nishimura

doi:10.4161/onci.25801

Long peptide-based cancer immunotherapy targeting tumor antigen-specific CD4⁺ and CD8⁺ T cells

Oncoimmunology. 2013 Sep 1;2(9):e25801. doi: 10.4161/onci.25801. Epub 2013 Jul 29.

Authors

Yusuke Tomita¹, Yasuharu Nishimura

Affiliation

¹ Department of Immunogenetics, Graduate School of Medical Sciences; Kumamoto University; Kumamoto, Japan ; Department of Respiratory Medicine; Graduate School of Medical Sciences; Kumamoto University; Kumamoto, Japan.

Abstract

CD4⁺ T cells promote cytotoxic T lymphocyte (CTL)-mediated anticancer immune responses. We have recently identified ideal tumor-associated antigen (TAA)-derived long peptides (LPs) that elicit not only TAA-specific T_H1 response, but also CTLs, through cross-presentation. The LP-specific T_H1 cell responses were augmented in cancer patients vaccinated with CTL epitopes. Our findings support the clinical application of LP-based immunotherapy.

Keywords: Type 1 helper T cell; cDNA microarray analysis; cross-presentation; helper T-cell epitope; peptide vaccine; tumor-associated antigen.

Publication types

Research Support, Non-U.S. Gov't